tiprankstipranks
Trending News
More News >
Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
US Market

Radiopharm Theranostics Limited Sponsored ADR (RADX) Stock Forecast & Price Target

Compare
49 Followers
See the Price Targets and Ratings of:

RADX Analyst Ratings

Strong Buy
3Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Radiopharm
Theranostics Limited Sponsored ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RADX Stock 12 Month Forecast

Average Price Target

$20.33
▲(270.31% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Radiopharm Theranostics Limited Sponsored ADR in the last 3 months. The average price target is $20.33 with a high forecast of $30.00 and a low forecast of $15.00. The average price target represents a 270.31% change from the last price of $5.49.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","31":"$31","9.25":"$9.25","16.5":"$16.5","23.75":"$23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,6.60923076923077,8.55846153846154,10.507692307692308,12.456923076923077,14.406153846153847,16.355384615384615,18.304615384615385,20.253846153846155,22.203076923076924,24.152307692307694,26.101538461538464,28.05076923076923,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,5.865384615384615,7.070769230769231,8.276153846153846,9.481538461538461,10.686923076923076,11.892307692307693,13.097692307692308,14.303076923076922,15.508461538461537,16.713846153846152,17.91923076923077,19.12461538461538,{"y":20.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.66,5.455384615384616,6.250769230769231,7.046153846153846,7.841538461538462,8.636923076923077,9.432307692307692,10.227692307692308,11.023076923076923,11.818461538461538,12.613846153846154,13.409230769230769,14.204615384615384,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.86,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.16,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.61,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.49,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.64,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.74,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$30.00Average Price Target$20.33Lowest Price Target$15.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
$12$15
Buy
173.22%
Upside
Reiterated
12/17/25
Radiopharm price target raised to $15 from $12 at MaximRadiopharm price target raised to $15 from $12 at Maxim
JonesTrading Analyst forecast on RADX
JonesTrading
JonesTrading
$30
Buy
446.45%
Upside
Reiterated
12/16/25
Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential
B. Riley Securities Analyst forecast on RADX
B. Riley Securities
B. Riley Securities
$13$16
Buy
191.44%
Upside
Reiterated
12/16/25
Radiopharm price target raised to $16 from $13 at B. RileyRadiopharm price target raised to $16 from $13 at B. Riley
Brookline Capital Markets Analyst forecast on RADX
Brookline Capital Markets
Brookline Capital Markets
$18
Buy
227.87%
Upside
Initiated
07/21/25
Radiopharm initiated with a Buy at BrooklineRadiopharm initiated with a Buy at Brookline
ThinkEquity Analyst forecast on RADX
ThinkEquity
ThinkEquity
$15
Buy
173.22%
Upside
Initiated
05/12/25
Radiopharm initiated with a Buy at ThinkEquityRadiopharm initiated with a Buy at ThinkEquity
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
$12$15
Buy
173.22%
Upside
Reiterated
12/17/25
Radiopharm price target raised to $15 from $12 at MaximRadiopharm price target raised to $15 from $12 at Maxim
JonesTrading Analyst forecast on RADX
JonesTrading
JonesTrading
$30
Buy
446.45%
Upside
Reiterated
12/16/25
Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential
B. Riley Securities Analyst forecast on RADX
B. Riley Securities
B. Riley Securities
$13$16
Buy
191.44%
Upside
Reiterated
12/16/25
Radiopharm price target raised to $16 from $13 at B. RileyRadiopharm price target raised to $16 from $13 at B. Riley
Brookline Capital Markets Analyst forecast on RADX
Brookline Capital Markets
Brookline Capital Markets
$18
Buy
227.87%
Upside
Initiated
07/21/25
Radiopharm initiated with a Buy at BrooklineRadiopharm initiated with a Buy at Brookline
ThinkEquity Analyst forecast on RADX
ThinkEquity
ThinkEquity
$15
Buy
173.22%
Upside
Initiated
05/12/25
Radiopharm initiated with a Buy at ThinkEquityRadiopharm initiated with a Buy at ThinkEquity
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Radiopharm Theranostics Limited Sponsored ADR

1 Month
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
+6.50%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +6.50% per trade.
3 Months
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
+10.48%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +10.48% per trade.
1 Year
Success Rate
3/5 ratings generated profit
60%
Average Return
+10.44%
reiterated a buy rating 11 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +10.44% per trade.
2 Years
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
+10.44%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +10.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RADX Analyst Recommendation Trends

Rating
Jul 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
7
8
9
7
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
8
9
7
8
In the current month, RADX has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RADX average Analyst price target in the past 3 months is 20.33.
Each month's total comprises the sum of three months' worth of ratings.

RADX Financial Forecast

RADX Earnings Forecast

Next quarter’s earnings estimate for RADX is -$2.00 with a range of -$2.00 to -$2.00. The previous quarter’s EPS was -$1.95. RADX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RADX has Performed in-line its overall industry.
Next quarter’s earnings estimate for RADX is -$2.00 with a range of -$2.00 to -$2.00. The previous quarter’s EPS was -$1.95. RADX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RADX has Performed in-line its overall industry.

RADX Sales Forecast

Next quarter’s sales forecast for RADX is $1.21M with a range of $1.21M to $1.21M. The previous quarter’s sales results were $1.43M. RADX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RADX has Performed in-line its overall industry.
Next quarter’s sales forecast for RADX is $1.21M with a range of $1.21M to $1.21M. The previous quarter’s sales results were $1.43M. RADX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RADX has Performed in-line its overall industry.

RADX Stock Forecast FAQ

What is RADX’s average 12-month price target, according to analysts?
Based on analyst ratings, Radiopharm Theranostics Limited Sponsored ADR’s 12-month average price target is 20.33.
    What is RADX’s upside potential, based on the analysts’ average price target?
    Radiopharm Theranostics Limited Sponsored ADR has 270.31% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RADX a Buy, Sell or Hold?
          Radiopharm Theranostics Limited Sponsored ADR has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Radiopharm Theranostics Limited Sponsored ADR’s price target?
            The average price target for Radiopharm Theranostics Limited Sponsored ADR is 20.33. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $30.00 ,the lowest forecast is $15.00. The average price target represents 270.31% Increase from the current price of $5.49.
              What do analysts say about Radiopharm Theranostics Limited Sponsored ADR?
              Radiopharm Theranostics Limited Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of RADX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.